Oral mucositis

被引：165

作者：

Raber-Durlacher, Judith E. ^{[1
]}

Elad, Sharon ^{[2
]}

Barasch, Andrei ^{[3
]}

机构：

[1] Acad Ctr Dent Amsterdam, Dept Periodontol, NL-1066 EA Amsterdam, Netherlands

[2] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Oral Med, Jerusalem, Israel

[3] Univ Alabama Birmingham, Birmingham, AL 35294 USA

来源：

ORAL ONCOLOGY | 2010年 / 46卷 / 06期

关键词：

Oral mucositis; Mucosal barrier injury; Ulceration; Cancer; Toxicity; Chemotherapy; Radiation; Head and neck cancer; Haematopoietic stem cell transplantation; Graft versus Host Disease; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; BEAM-CONDITIONING CHEMOTHERAPY; CLINICAL-PRACTICE GUIDELINES; CANCER-PATIENTS; CHALLENGING COMPLICATION; RADIATION-THERAPY; ECONOMIC OUTCOMES; NECK-CANCER; HEAD;

D O I：

10.1016/j.oraloncology.2010.03.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mucosal damage is one of the most common adverse effects of radiotherapy and of cytotoxic therapy for cancer. With prevalence between 10% and 100%, depending of the cytotoxic regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. In this paper we address oral mucositis and discuss its pathobiology, risk factors, impact and management in view of the most recent evidence. Despite of clear progress and the development of clinical guidelines, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：452 / 456

页数：5

共 49 条

[1]

APRILE G, 2009, CANCER, V112, P284

[2] Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions [J].

Barasch, A ;

Peterson, DE .

ORAL ONCOLOGY, 2003, 39 (02) :91-100

[3]

Barasch A, 2009, BIOL-TARGETS THER, V3, P111

[4]

Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33

[5]

Bensinger William, 2008, J Natl Compr Canc Netw, V6 Suppl 1, pS1

[6] Prospective Oral Mucositis Audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European blood and marrow transplantation mucositis advisory group [J].

Blijlevens, Nicole ;

Schwenkglenks, Matthias ;

Bacon, Pamela ;

D'Addio, Alessandra ;

Einsele, Hermann ;

Maertens, Johan ;

Niederwieser, Dietger ;

Rabitsch, Werner ;

Roosaar, Ann ;

Ruutu, Tapani ;

Schouten, Harry ;

Stone, Rebecca ;

Vokurka, Samuel ;

Quinn, Barry ;

McCann, Shaun .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1519-1525

[7] Mucositis: from febrile neutropenia to febrile mucositis [J].

Blijlevens, Nicole M. A. ;

Logan, Richard M. ;

Netea, Mihai G. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 :I36-I40

[8] Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview [J].

Blijlevens, NMA ;

Donnelly, JP ;

De Pauw, BE .

BONE MARROW TRANSPLANTATION, 2000, 25 (12) :1269-1278

[9] TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation [J].

Bogunia-Kubik, K ;

Polak, M ;

Lange, A .

BONE MARROW TRANSPLANTATION, 2003, 32 (06) :617-622

[10]

Cleeland Charles S, 2007, J Natl Cancer Inst Monogr, P16

← 1 2 3 4 5 →